Program
Acetaminophen
Also written as “Paracetamol”, “IV Acetaminophen” and “Experimental paracetamol formulation”.
Its studies are mostly in Pain · Pain, Postoperative · Migraine Disorders · Common Cold · Fever, led by 26 companies.
Drug pageAcetaminophen: every studyMany companies study it; this page follows only the 123 they lead. All 662 studies, academic ones too, with its approvals and label.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Johnson & Johnsonits history only | 390 open or running | phase 4since Sep 13, 2005 | Sep 13, 2005 | none ahead |
| GlaxoSmithKlineits history only | 240 open or running | phase 4since Feb 18, 2010 | Jun 2, 2006 | none ahead |
| Keenova Therapeuticsits history only | 110 open or running | phase 4since Feb 5, 2016 | Nov 14, 2006 | none ahead |
| Allodynic Therapeuticsits history only | 60 open or running | phase 3since Jun 8, 2017 | Feb 17, 2017 | none ahead |
| Novartisits history only | 60 open or running | phase 4since Jun 19, 2007 | Jan 29, 2007 | none ahead |
| Sanofiits history only | 41 open or running | phase 3since Feb 12, 2007 | Feb 12, 2007 | May 17, 2027phase 2 · NCT06647407 |
| Sun Pharmaceutical Industriesits history only | 40 open or running | no phasesince Feb 18, 2010 | Feb 18, 2010 | none ahead |
| AFT Pharmaceuticalsits history only | 30 open or running | phase 3since Aug 16, 2011 | Aug 16, 2011 | none ahead |
| Nevakarits history only | 30 open or running | phase 2since Jul 8, 2019 | Jul 8, 2019 | none ahead |
| Angelini Pharmaits history only | 20 open or running | phase 2since Apr 9, 2015 | Apr 9, 2015 | none ahead |
| Baxter Healthcareits history only | 20 open or running | phase 3since Nov 29, 2006 | Nov 29, 2006 | none ahead |
| Grünenthalits history only | 20 open or running | phase 1since Apr 27, 2017 | Apr 27, 2017 | none ahead |
| Hamad Medicalits history only | 20 open or running | phase 4since Dec 12, 2019 | Jun 21, 2013 | none ahead |
| Laboratorios Silanes S.A. de C.V.its history only | 20 open or running | phase 3since Mar 3, 2025 | Jun 15, 2022 | none ahead |
| Sinteticaits history only | 20 open or running | phase 2since Dec 23, 2015 | Dec 23, 2015 | none ahead |
| Ascension Healthits history only | 10 open or running | phase 4since Aug 23, 2018 | Aug 23, 2018 | none ahead |
| AstraZenecaits history only | 10 open or running | phase 1since Aug 24, 2018 | Aug 24, 2018 | none ahead |
| Boehringer Ingelheimits history only | 10 open or running | phase 3since Jul 7, 2014 | Jul 7, 2014 | none ahead |
| Bristol-Myers Squibbits history only | 10 open or running | phase 4since Jun 23, 2006 | Jun 23, 2006 | none ahead |
| Eurofarma Laboratoriosits history only | 10 open or running | phase 3since Oct 5, 2021 | Oct 5, 2021 | none ahead |
| HALEONits history only | 10 open or running | phase 1since Feb 28, 2025 | Feb 28, 2025 | none ahead |
| Intarcia Therapeuticsits history only | 10 open or running | phase 1since Dec 21, 2015 | Dec 21, 2015 | none ahead |
| Par Healthits history only | 10 open or running | phase 1since Apr 1, 2008 | Apr 1, 2008 | none ahead |
| QC Kinetixits history only | 10 open or running | phase 2since Feb 6, 2023 | Feb 6, 2023 | none ahead |
| Reckittits history only | 10 open or running | phase 3since Oct 26, 2010 | Oct 26, 2010 | none ahead |
| Rottapharmits history only | 10 open or running | phase 3since May 9, 2005 | May 9, 2005 | none ahead |
Also a collaborator on its studies: Nevakar Injectables, Cross, Cross Research, Premier Research Group, Aptuit, MDS Pharma Services and PriCara, Unit of Ortho-McNeil.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of every company. Pick one to see its own:
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 46 studies since Jun 23, 2011.
- Jun 23, 2020Phase 2 study in PainJohnson & Johnson · NCT04447040 · 304 enrolled · United States
- Jul 27, 2020Phase 2 study in Pain, PostoperativeNevakar · NCT04495283 · 87 enrolled · United States
- Oct 5, 2021Eurofarma Laboratorios’ first study: phase 3 study in Common ColdNew to Eurofarma LaboratoriosEurofarma Laboratorios · NCT05118672 · 567 enrolled · Brazil
- Jun 15, 2022Laboratorios Silanes S.A. de C.V.’s first study: phase 1 study in PainNew to Laboratorios Silanes S.A. de C.V.Laboratorios Silanes S.A. de C.V. · NCT05428306 · 42 enrolled · Mexico
- Dec 27, 2022Phase 2 study in Migraine DisordersAllodynic Therapeutics · NCT05685225 · United States
- Feb 6, 2023QC Kinetix’s first study: phase 2 study in Osteoarthritis, KneeNew to QC KinetixQC Kinetix · NCT05742763 · United States
- Feb 27, 2023Phase 3 study in PainJohnson & Johnson · NCT05761574 · 447 enrolled · United States
- Apr 25, 2023Phase 3 study in Orthodontic PainJohnson & Johnson · NCT05845008 · United States
- Apr 25, 2023Phase 1 study in Orthodontic PainJohnson & Johnson · NCT05844995 · 24 enrolled · United States
- May 11, 2023Phase 3 study in PainJohnson & Johnson · NCT05868122 · 143 enrolled · United States
- Jan 30, 2024Phase 2 study in Migraine DisordersAllodynic Therapeutics · NCT06245902 · 92 enrolled · United States
- Oct 16, 2024Phase 2 study in Meningococcal ImmunizationSanofi · NCT06647407 · 750 enrolled · Brazil, Czechia, Denmark and more
- Feb 28, 2025HALEON’s first study: phase 1 study in FeverNew to HALEONHALEON · NCT06855576 · 54 enrolled · Germany
- Mar 3, 2025Phase 3 study in ArthralgiaLaboratorios Silanes S.A. de C.V. · NCT06863636 · 231 enrolled · Mexico
Ahead
- May 17, 2027Primary completion: phase 2 study in Meningococcal ImmunizationSanofi · NCT06647407
TargetBeta
“Cyclooxygenase inhibitor; Anandamide amidohydrolase inhibitor; Vanilloid receptor opener”ChEMBL 37, by rule
Studies
The newest 60 of 123 led by companies developing it. Each opens its study page. Every study on its drug page →
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT06863636Arthralgia · Mexico | 3 | Completed | Laboratorios Silanes S.A. de C.V. | Oct 30, 2025 | 231 |
| NCT06855576Fever · Germany | 1 | Completed | HALEON | Apr 17, 2025 | 54 |
| NCT06647407Meningococcal Immunization · Brazil, Czechia, Denmark and more | 2 | Active, not recruiting | Sanofi | May 17, 2027 | 750 |
| NCT06245902Migraine Disorders · United States | 2 | Completed | Allodynic Therapeutics | Feb 8, 2018 | 92 |
| NCT05868122Pain · United States | 3 | Completed | Johnson & Johnson | May 25, 2024 | 143 |
| NCT05845008Orthodontic Pain · United States | 3 | Withdrawn | Johnson & Johnson | Jul 15, 2024 | 0 |
| NCT05844995Orthodontic Pain · United States | 1 | Completed | Johnson & Johnson | Feb 12, 2024 | 24 |
| NCT05761574Pain · United States | 3 | Completed | Johnson & Johnson | May 17, 2024 | 447 |
| NCT05742763Osteoarthritis, Knee · United States | 2 | Withdrawn | QC Kinetix | Oct 7, 2024 | 0 |
| NCT05685225Migraine Disorders · United States | 2 | Withdrawn | Allodynic Therapeutics | Dec 2, 2025 | 0 |
| NCT05428306Pain · Mexico | 1 | Completed | Laboratorios Silanes S.A. de C.V. | Nov 6, 2018 | 42 |
| NCT05118672Common Cold · Brazil | 3 | Completed | Eurofarma Laboratorios | Aug 26, 2025 | 567 |
| NCT04495283Pain, Postoperative · United States | 2 | Completed | Nevakar | Nov 12, 2020 | 87 |
| NCT04447040Pain · United States | 2 | Completed | Johnson & Johnson | Apr 9, 2021 | 304 |
| NCT04265456Pain, Postoperative · United States | 1 | Completed | Nevakar | Jun 15, 2020 | 63 |
| NCT04230252Healthy · Korea, Republic of | 1 | Completed | Johnson & Johnson | Feb 10, 2020 | 30 |
| NCT04214691Healthy · Korea, Republic of | 1 | Completed | Johnson & Johnson | Jan 16, 2020 | 30 |
| NCT04199572Musculoskeletal Injury · Qatar | 4 | Completed | Hamad Medical | Feb 21, 2023 | 162 |
| NCT04018612Pain, Postoperative · United States | 2 | Completed | Nevakar | Jul 26, 2019 | 110 |
| NCT03879408Pain · United States | 2 | Completed | Johnson & Johnson | Nov 7, 2019 | 290 |
| NCT03649165Neurofibromatosis 1 · United States | 1 | Completed | AstraZeneca | Oct 21, 2018 | 24 |
| NCT03702023Post Electrophysiology Procedure Pain · United States | 4 | UNKNOWN | Ascension Health | Jun 1, 2020 | 200 |
| NCT03428230Pain, Postoperative · Switzerland | 2 | Completed | Sintetica | Oct 22, 2019 | 60 |
| NCT03415243Common Cold · United States | 1 | Completed | GlaxoSmithKline | Mar 29, 2018 | 28 |
| NCT03368664Multiple Sclerosis · France, Italy, Poland and more | 3 | Terminated | Sanofi | May 4, 2021 | 16 |
| NCT03201393Radiculopathy · United States | 2 | Completed | Allodynic Therapeutics | Jul 26, 2018 | 12 |
| NCT03194555Headache · United States | 2 | Completed | Allodynic Therapeutics | Jul 26, 2018 | 12 |
| NCT03185143Migraine With and Without Aura · United States | 3 | Completed | Allodynic Therapeutics | May 7, 2018 | 36 |
| NCT03137030Opioid-Related Disorders · United States | 1 | Withdrawn | Grünenthal | Jan 2018 | 0 |
| NCT03137017Opioid-Related Disorders · United States | 1 | Withdrawn | Grünenthal | Nov 2017 | 0 |
| NCT03061734Migraine Disorders · United States | 2 | Completed | Allodynic Therapeutics | Feb 8, 2018 | 92 |
| NCT02974114Pain · United Kingdom | 4 | Terminated | GlaxoSmithKline | Feb 6, 2017 | 21 |
| NCT02902666Healthy | 1 | Completed | Angelini Pharma | May 2016 | 46 |
| NCT02848729Pain · United States | 4 | Completed | Keenova Therapeutics | Mar 2016 | 50 |
| NCT02735122Post Operative Dental Pain · United States | 3 | Completed | Johnson & Johnson | Oct 5, 2016 | 420 |
| NCT02746263Pain, Postoperative · United States | 4 | Terminated | Keenova Therapeutics | May 5, 2016 | 1 |
| NCT02689063Pain, Postoperative · United States | 3 | Completed | AFT Pharmaceuticals | Jun 30, 2017 | 276 |
| NCT02678416Pain · United States | 4 | Completed | Keenova Therapeutics | Jun 13, 2016 | 79 |
| NCT02678234Respiratory Tract Infections | 3 | Withdrawn | GlaxoSmithKline | Apr 1, 2017 | 0 |
| NCT02730364Respiratory Tract Infections | 3 | Withdrawn | GlaxoSmithKline | Apr 1, 2017 | 0 |
| NCT02654860Phase 1: Pain Management · Switzerland | 2 | Completed | Sintetica | Feb 2019 | 69 |
| NCT02641899Healthy · United States | 1 | Completed | Intarcia Therapeutics | Mar 2016 | 33 |
| NCT02583594Multiple Sclerosis, Chronic Progressive · Spain | 1 | Completed | Sanofi | Mar 2016 | 24 |
| NCT02422966Ductus Arteriosus, Patent · Italy | 2 | Completed | Angelini Pharma | Jan 2019 | 110 |
| NCT02320708Toothache · United States | 2 | Completed | Johnson & Johnson | Apr 30, 2015 | 240 |
| NCT02311881Pain · United States | 3 | Completed | GlaxoSmithKline | Feb 2016 | 960 |
| NCT02183688Migraine Disorders | 3 | Completed | Boehringer Ingelheim | Jan 2003 | 1,889 |
| NCT01973205Migraine Disorders · United States | 3 | Completed | Novartis | Jul 2014 | 900 |
| NCT01960114Toothache · United States | 2 | Completed | Johnson & Johnson | Apr 2014 | 403 |
| NCT01891435Fever · Qatar | – | Completed | Hamad Medical | Dec 2011 | 434 |
| NCT01842633Pain · United States | 3 | Terminated | GlaxoSmithKline | Mar 31, 2015 | 365 |
| NCT01822665Gastrointestinal Mucosal Damage · United States | 4 | Completed | GlaxoSmithKline | Jul 2012 | 28 |
| NCT01814878Pain, Postoperative | 3 | Completed | Johnson & Johnson | Jan 2011 | 320 |
| NCT01767428Fever | 1 | Completed | GlaxoSmithKline | Apr 2010 | 30 |
| NCT01728246Osteoarthritis · Philippines | 4 | Completed | Johnson & Johnson | May 2008 | 473 |
| NCT01686646Common Cold · United Kingdom | 3 | Completed | GlaxoSmithKline | Nov 2012 | 240 |
| NCT01635101Acute Pain · United States | 3 | Completed | Keenova Therapeutics | Aug 2015 | 197 |
| NCT01592227Pain · United States | 1 | Completed | GlaxoSmithKline | Dec 2009 | 30 |
| NCT01568749Agnosia · United States | 1 | Completed | GlaxoSmithKline | Aug 2009 | 14 |
| NCT01551836Healthy Volunteer · United Kingdom | 1 | Completed | GlaxoSmithKline | Jun 2009 | 12 |
How it is read
Names in the registry
- “Acetaminophen”, 24 entries
- “Paracetamol”, 10 entries
- “IV Acetaminophen”, 10 entries
- “Experimental paracetamol formulation”, 5 entries
- “acetaminophen”, 5 entries
Conditions, from the studies’ own filings
- Pain, 28 studies
- Pain, Postoperative, 13 studies
- Migraine Disorders, 8 studies
- Common Cold, 7 studies
- Fever, 7 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.